Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Our lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, recently completed a proof-of-concept, phase 2A study (TIME-2), and the HIF1-α stabilization program is rapidly progressing toward the clinic with first-in-human trials expected to start in early 2016.
|HQ||Blue Ash, OH, US||Map|
Aerpio Therapeutics total Funding
Aerpio Therapeutics latest funding size
Time since last funding
|5 years ago|
Aerpio Therapeutics investors
|Venture Investors, Novartis Venture Fund, OrbiMed, Satter Investment Management|
When was Aerpio Therapeutics founded?
Aerpio Therapeutics was founded in 2011.
Who are Aerpio Therapeutics key executives?
Aerpio Therapeutics's key executives are Joseph Gardner, Brandi Soldo and Gina Marek.
Who are Aerpio Therapeutics competitors?
Competitors of Aerpio Therapeutics include Transgene, DBV Technologies and Synthace.
Where is Aerpio Therapeutics headquarters?
Aerpio Therapeutics headquarters is located at The Landings II, 9987 Carver Rd #420, Blue Ash.
Where are Aerpio Therapeutics offices?
Aerpio Therapeutics has an office in Blue Ash.
How many offices does Aerpio Therapeutics have?
Aerpio Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies